An Open-Label Phase 1B/2 Study to Evaluate the Safety and Efficacy of Tabelecleucel in Combination with Pembrolizumab in Subjects with Platinum -pre-treated Recurrent /Metastatic Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma

Brief description of study

The purpose of this research study is to: • Assess the safety of tabelecleucel in combination with pembrolizumab. This will include looking at what side effects occur and how often they occur. • Identify the most effective and well-tolerated dose of tabelecleucel in combination with pembrolizumab (also called the maximum tolerated dose). • Assess the effects of tabelecleucel in combination with pembrolizumab on your tumor progression. You are being invited to take part in this research study because you have previously been treated with platinum-based therapy and have recurrent/metastatic Nasopharyngeal Carcinoma which has been associated with the Epstein - Barr virus (EBV).


Clinical Study Identifier: s18-00720
ClinicalTrials.gov Identifier: NCT03769467
Principal Investigator: Zujun Li
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.